Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.57 |
| ▸ | CDK1 | P06493 | 10/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 9/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.57 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 0.57 |
| ▸ | NEK2 | P51955 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793728 | 0.87 | CDK2 (0.75) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL6787539 | 0.79 | CDK2 (0.56) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL6791914 | 0.76 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL7113916 | 0.73 | CDK2 (0.75) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL6798010 | 0.73 | CDK2 (0.45) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL4919889 | 0.72 | CDK2 (0.43) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL6791643 | 0.72 | CDK2 (0.71) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL4916505 | 0.71 | CDK2 (0.58) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL6791789 | 0.71 | CDK2 (0.54) | CDK2CCNA2CCNA1CDK1CCNB2 | |
| SCHEMBL12589620 | 0.70 | CDK2 (0.76) | CDK2CCNA2CCNA1CDK1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | CDK2 13/4885CCNA2 15/4885CCNA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.